Business Wire

Intersolar Europe: Agrivoltaics – Harvesting Solar Power

27.4.2023 13:21:00 EEST | Business Wire | Press release

Share

The world population is growing, as is the demand for food. To tackle the climate crisis, the world needs both agricultural land and surfaces for the deployment of photovoltaics (PV). In line with the zeitgeist, agricultural PV brings together both worlds: agriculture and renewable power generation. Solar modules built over fields can transport us into the new energy world faster, all the while protecting important agricultural yields. This is why Intersolar Europe – The world’s leading exhibition for the solar industry – will be focusing on the topic. Together with the French-German Office for Energy Transition (DFBEW), Intersolar Europe will be presenting new business models and best practices from France and Germany. Agricultural PV is also on the agenda of the Intersolar Europe Conference. Intersolar Europe will be held as part of The smarter E Europe, the continent’s largest platform for the energy industry, from June 14 to 16, 2023 in Munich.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230427005413/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Trend topic Agrivoltaics will be presented at Intersolar Europe 2023 in Munich, Germany. (Photo: Solar Promotion GmbH)

Agrivoltaics is currently trending. Agrivoltaics projects are demonstrating how the generation of solar power and agriculture can go hand in hand and benefit from each other and how the conflict over available surfaces can be cleverly solved.

Renewable electricity for decentralized self-consumption is a great opportunity for agricultural operations adding solar installations to their assets. It allows them to use the renewable power generated on their land and reduce their bills for grid-supplied electricity. If they have excess electricity, they can sell it, which provides an additional source of income. What’s more, agricultural PV installations can boost resilience and increase the yield of agricultural operations because solar modules offer protection against heavy rain, hail or drought for fruit and special crops.

Europe recognizes potential

In many European countries, more and more farmers and political decision-makers are recognizing the potential of agricultural PV. Italy, for instance, recently passed new regulations that determine which agricultural PV installations are eligible for funding from a government incentive program with a scope of 1.1 billion euros, giving a boost to innovative agricultural PV installations. While Germany is testing agricultural PV in combination with the cultivation of apples, for example, in Gelsdorf in Rhineland Palatinate, France has started installing solar modules over rows of vines.

With tractor and tracker – trend towards dual use

Covering crops with raised solar modules – as French winegrowers are doing now – is particularly interesting because it is favorable for winegrowing, as well as for fruit, berries or herbs, and any plants that prefer partial shade. Furthermore, solar roofs can replace conventional hail netting or polytunnels, and they protect the crops from drying out.

Integrating solar installations into agriculture opens up many areas of application. Free-standing solar installations on fields and meadows can also be equipped with trackers that follow the course of the sun, which increases the yield compared with conventional, fixed modules, by around 20 percent. The solar panels can also be moved out of the way of any working agricultural machinery.

Agri PV: Hot topic at Intersolar Europe

To learn all there is to know about solar power generation in agriculture, join us at Intersolar Europe. The session “Agricultural PV in France and Germany: Potential, Business Models and Best Practice” (Agri-PV in Deutschland und Frankreich: Potenziale, Geschäftsmodelle und Best Practices) on June 15 at 3:20pm CEST at the Intersolar Forum will be presenting an extensive overview of solutions and applications that already work. An even more hands-on experience will be offered by many exhibitors, such as BayWa r.e. AG, Fraunhofer Institute for Solar Energy Systems (ISE), Next2Sun GmbH, Goldbeck Solar GmbH, SunFarming GmbH and many more. The program of the Intersolar Europe Conference will be looking into agricultural PV one day before the start of the exhibition itself. Experts will be discussing the potential of solar power in agriculture.

Intersolar Europe will be held from June 14–16, 2023 as part of The smarter E Europe 2023 at Messe München. Over 85,000 visitors from all corners of the globe are expected to attend. More than 2,200 exhibitors across 17 exhibition halls covering 180,000 square meters will be waiting for them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Peggy Zilay
Spokesperson
The smarter E Europe
+49 7231 58598-240
zilay@solarpromotion.com

Juliane Heermeier
Account Manager
+49 151 41482446
juliane.heermeier@fischerappelt.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye